SREBF2 and pheochromocytoma-paraganglioma: Srebf2 was significantly upregulated (p < 0.05) in breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), kidney chromophobe (KICH), liver hepatocellular carcinoma (LIHC), and lung squamous cell carcinoma (LUSC), while significantly downregulated (p < 0.05) in colon adenocarcinoma (COAD), glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD) and pheochromocytoma and paraganglioma (PCPG) (Figure 8).